Kevzara is a MAB from Sanofi/Regeneron which entered the Covid trial arena. Sought to control IL-6 by blocking IL-6 receptors just as it does for the treatment of Rheumatoid Arthritis. Trial ended with some benefit to ARD patients but little benefit to mild cases. Brilacidin data presented for OM states the following with regard to IL-6:
Immunomodulatory activity of brilacidin HDPs are a key component of the innate immune system and have multiple modes of action: immunomodulatory, anti-inflammatory, and rapid microbial killing. Radiation and/or chemotherapy results in oxidative stress and an inflammatory response in oral mucosa which leads to activation of transcription factors and signal transduction pathways, including NF-?B and p53. mRNA levels of TNF-a and IL-1ß in oral mucosal tissue correlates with severity of mucosal injury. NF-kB activation induces inflammatory cytokines, e.g., IL-6, IL-1ß, TNF-a, that affect mucosal integrity. These pro-inflammatory cytokines initiate an inflammatory cascade leading to activation of matrix metalloproteinases (MMPs) and Monocyte Chemoattractant Protein-1 (MCP-1) that further damages tissue. Ulceration develops and creates portals for bacterial entry and colonization. https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=25748
News 
Market Data 
Discover 
